📷 Image Credits: ET Now
Emcure Pharmaceuticals IPO has been making headlines recently, especially due to the involvement of Namita Thapar, known for her appearance on Shark Tank India. The IPO consists of fresh issuance of equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore equity shares amounting to Rs 1,152 crore, at the upper end of the price band. This brings the total public size to Rs 1,952 crore.
What’s interesting to note is that Namita Thapar had acquired shares in Emcure at a weighted average cost of acquisition (WACA) of Rs 3.44 apiece, indicating a potential significant profit margin post the IPO listing.
The latest GMP (Grey Market Premium) of the Emcure Pharma IPO linked to Namita Thapar has been quite positive, with the IPO set to open for subscription this week. This development has garnered attention from investors and market watchers alike.
In addition to the Emcure Pharmaceuticals IPO news, there have been updates on Hindenburg Research receiving a ‘show cause’ notice from SEBI, and stocks to watch such as Tata Steel, Patanjali Foods, DCX Systems, IOL Chemicals, and KPI Green Energy.
Moreover, stocks like L&T, IndiGo, ONGC, Bajaj Finance, and Anant Raj are being recommended for purchase with specific share price targets. This showcases the dynamic landscape of the stock market, offering various opportunities and challenges for investors.
Overall, the Emcure Pharmaceuticals IPO, coupled with the involvement of Namita Thapar, has added an intriguing dimension to the market, attracting attention from both seasoned investors and new entrants seeking to capitalize on potential opportunities.
